Polar Capital

16 Palace Street
London, SW1E 5JD

Website: co.uk

Firm Size

  • Assets Under Management (AUM):$17.7 Billion
  • Number of Funds:24
  • Employees:192
  • Firm Type:Hedge Fund


Description

Polar Capital is an investment management company based in London, England. The firm specializes in long-only and alternative investment strategies across a wide range of asset classes, including equities, fixed income, and multi-asset solutions. With more than 30 years of experience in the industry, Polar Capital has built a reputation for delivering consistent investment performance and providing innovative investment solutions to investors globally. The company follows a multi-boutique approach, which means each investment team operates independently, allowing for a diverse range of investment styles and approaches. This approach ensures that clients have access to a variety of expertise and perspectives, helping them to achieve their specific investment goals. Polar Capital's investment process is research-driven, with a strong emphasis on rigorous bottom-up analysis and understanding the fundamentals of companies and markets. The company's investment teams are composed of experienced professionals with deep sector knowledge and expertise, who actively seek out attractive investment opportunities around the world. In addition to its strong investment capabilities, Polar Capital places great importance on client service and building long-term relationships. The company works closely with its clients to understand their unique needs and offers personalized investment solutions that align with their objectives and risk tolerance. Overall, Polar Capital is a well-established investment management firm based in London, known for its expertise in various asset classes, research-driven approach, and client-centric focus.

Latest News

Powered by

Dec 07, 2023: Spyre Therapeutics Announces $180 Million Private Placement
Spyre Therapeutics, Inc. ("Spyre") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $180 million to the Company, before deducting placement agent fees and offering expenses. The PIPE financing included participation from both new and existing investors, including Access Biotechnology, Venrock Healthcare Capital Partners, Perceptive Advisors, RTW Investments, LP, Braidwell LP, Fairmount, Cormorant Asset Management, Polar Capital, Boxer Capital, Deep Track Capital, Great Point Partners LLC, Affinity Asset Advisors, Commodore Capital, Woodline Partners LP, a leading biotechnology investor associated with one of the largest alternative asset managers, and a large investment management firm.